Navigation Links
PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments
Date:10/4/2007

PC-LDM ENSURES COMPLIANCE WITH THE SEND FORMAT FOR DATA EXCHANGE AND

ELECTRONIC SUBMISSIONS

FOSTER CITY, Calif., Oct. 4 /PRNewswire/ -- PointCross announced today the release of its PC-LDM(TM) Suite that allows Pharmaceutical and Biotechnology companies to instantly become compliant with SEND (Standard for Exchange of Non-Clinical Data), a CDISC (Clinical Data Interchange Standards Consortium) standard. FDA is anticipating that SEND will replace its current paper or PDF submission formats as indicated in the Federal Register Notice for a Regulatory SEND Pilot (http://www.fda.gov/OHRMS/DOCKETS/98fr/E7-19468.pdf).

Besides SEND compliance, PC-LDM enables global companies to plan the pipeline of studies, exercise control over the conduct of studies, improve study quality, and gain visibility into study progress internally or at a CRO in a highly secure manner. It provides a single, secure environment to orchestrate multi-party workflows, and stakeholder interactions within an individual company, or across the extended enterprise including CROs.

PC-LDM is available either as a SaaS (Software-as-a-Service) model, or deployed within the enterprise.

"The FDA yesterday announced a Regulatory pilot to test the SEND standard and tools for submission and review of nonclinical data including animal toxicology and carcinogenicity data," said Seema Handu, Ph.D., of PointCross. "As the FDA moves towards data-centric electronic submissions, it is essential for sponsor companies to manage their study data throughout the lifecycle of a drug in a standard consistent manner," Dr. Handu added. Dr. Handu has led the SEND Team, a CDISC Working Committee, since its inception in 2002.

"PC-LDM will enable sponsor companies to meet FDA's requirements around SEND as well as other formats that may be required by other agencies," said Shree Nath, Ph.D. "PC-LDM's Semantic Data Exchanger allows data from legacy and on-going studies to be readily available for analysis and data mining, study comparison across similar chemical structures, decision making, and knowledge re-use. This is invaluable considering the amount of information loss due to legacy applications being retired, data currently locked permanently in documents, and inconsistent use of scientific terms by different CROs and individual scientists," added Dr. Nath.

PointCross' PC-LDM offering is built on Orchestra(TM), a scalable, secure SOA platform that provides core capabilities for defining, executing, analyzing and interpreting pre-clinical studies. PC-LDM includes vendor neutral XML-based Operational Data Models (ODMs) for all pre-clinical study types. It allows data exchange across industry standard applications and formats.

About PointCross

PointCross (http://www.pointcross.com) provides advanced strategic business solutions implemented on its Orchestra(TM) platform to knowledge-intensive industries including Pharmaceutical R&D and Upstream Oil and Gas. Besides PC-LDM, PointCross' IDDS (Integrated Drug Development Suite) includes other solutions for specific business processes within the R&D chain such as Lead Optimization, CMC Workbench, and Portfolio/Resource Management. Our customers have realized excellent ROIs and IRRs by using our solutions.


'/>"/>
SOURCE PointCross
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Sweet corn releases antioxidants on cooking
2. An International Growth Standard For Childs Releases By WHO
3. The National Governors Association Releases Guidelines For Outbreak Of Bird Flu
4. Eli Lilly Releases Digital Insulin Pen
5. CDC To Conduct Pre-clinical Trails Of BioDiems Intranasal Bird Flu Vaccine
6. Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress
7. Rural Canadians travel far for specialists: study
8. A new study surpasses Gene Therapy Hurdle
9. Tomato Sauce reduces Cancer Risk- Study
10. A question on study of Adult Stem Cell
11. Study on obesity and heart failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... DC (PRWEB) , ... April 24, 2017 , ... The ... recognized during ATA 2017: Telehealth 2.0 — the American Telemedicine Association’s annual conference, on ... Santana Telehealth Project for using telemedicine to improve the lives of the poor and ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner has ... Research Award. The award honors scholars exemplary in their capacity to communicate important ... has demonstrated the capacity to deepen the public’s understanding and appreciation of the ...
(Date:4/24/2017)... ... 24, 2017 , ... The California Dental Association Foundation’s two-day volunteer dental clinic, ... people during the April 22-23 event at the San Mateo Event Center. , ... to care, CDA Cares educates the public and policymakers about the importance of good ...
(Date:4/24/2017)... Houston (PRWEB) , ... April 24, 2017 , ... The ... an innovative technology that allows anyone, anywhere to track their cognitive health, and share ... to check their own brain health on the museum's website. , BrainCheck founder, Dr. ...
(Date:4/24/2017)... ... April 24, 2017 , ... My T Chai, a ... products are now available for purchase on RevNutrition.com, a popular website specializing in sales ... produced and popularized in ancient India and Siam. It spread across Asia and Africa ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: